Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end ZUG, Switzerland, October 7, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life ZUG, Switzerland, October 1, 2026 -- Oculis Holding AG
Oculis Announces Resignation of Lionel Carnot from Board of Directors ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in
ZUG, Switzerland, Sept. 17, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the Company’s Board of Directors. Attachment notification-of-managers-transaction-lionel-carnot-14-september-2026
The PIONEER program marks a key step toward potential first-in-class neuroprotection for optic neuritis and other neurological diseases, supported by positive Acuity Phase 2 data, FDA Breakthrough Therapy and EMA PRIME designations, and recent positive feedback from the FDA Neurology Division.
ZUG, Switzerland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company. Attachments Notification of managers' transaction - Anthony Rosenberg - 13 August 2026 RSU vest Notification of managers'
Transaction will enhance Oculis’ strategic flexibility and ownership of Privosegtor while driving long-term value creation Transaction consideration includes $3.8 million up-front cash payment at closing and up to 2,050,000 Oculis ordinary shares subject to lockup release over a period of up to 2
Company pivot to neuro-ophthalmology continues with Privosegtor positioned as lead late-stage asset through the registrational PIONEER program with expansion potential in acute multiple sclerosis (MS) relapses following positive FDA pre-IND feedback Enrollment progressing as planned in the
The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis (MS) relapses, addressing a significant unmet medical need The FDA confirmed that existing Privosegtor data can be cross-referenced for a new Investigational New
ZUG, Switzerland, July 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment Notification of managers' transaction - Riad Sherif - 5 July 2026 RSU vest
ZUG, Switzerland, July 02, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that
ZUG, Switzerland, July 2, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will
ZUG, Switzerland, June 15, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the Company’s Executive Committee. Attachment notification-of-managers-transaction-sylvia-cheung-10-june-2026
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an
ZUG, Switzerland, June 10, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company. Attachments Notification of managers' transaction - Arshad Khanani - 6 June 2026 RSU vest Notification of managers' transaction
ZUG, Switzerland, June 09, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the Company’s Executive Committee and Board of Directors. Attachment notification-of-managers-transaction-riad sherif-9-june-2026
PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potential of delivering a first-in-class precision medicine treatment in DED This FDA-aligned trial targets the specific TNFR1 genotype to maximize treatment effects, with ~70% of clinical sites already
ZUG, Switzerland, June 08, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that
ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment Notification of managers' transaction - Arshad Khanani - 29 May 2026 RSU vest
The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met The secondary endpoint of retinal thickness showed a substantial and persistent reduction with OCS-01 vs vehicle in both trials Oculis will focus its developmental
ZUG, Switzerland, May 28, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment Notification of managers' transaction - Arshad Khanani - 25 May 2026 RSU vest
ZUG, Switzerland, May 15, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company, the annual equity incentive awards granted to directors of the Company, and the one-time equity incentive award granted to a new
ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2026 Annual General Meeting held on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 12:00 p.m.
Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June 2026 Licaminlimab PREDICT-1 Trial in Active Site Recruitment Phase, Pioneering a Genotype-Driven Path to Precision Medicine in Dry Eye Disease
Special Protocol Assessment (SPA) agreement with the U.S. FDA provides regulatory alignment on the registrational path for Privosegtor in optic neuritis (ON) FDA Breakthrough Therapy and EMA PRIME designations in ON underscore the significant unmet need and therapeutic potential of Privosegtor as a